Off the wire
US Open schedule  • Chinese yuan strengthens to 6.3719 against USD Friday  • 2nd LD Writethru: S. Korea freezes interest rates at 1.5 percent  • China Hushen 300 index futures open higher Friday  • Market exchange rates in China -- Sept. 11  • China treasury bond futures open higher Friday  • US Open results  • Roundup: S. Korea freezes interest rates at record-low amid further cut expectations  • Chinese shares open lower Friday  • Tour of Britain cycling results  
You are here:   Home

Australian researchers find new treatment for type of cancer

Xinhua, September 11, 2015 Adjust font size:

Australian researchers have stumbled on a breakthrough treatment for a prevalent form of cancer, which they believe could be the biggest discovery in 30 years.

Researchers from Melbourne's Peter MacCallum Cancer Center used a drug developed in Sweden to treat ovarian cancer and tested it on esophageal cancer patients.

The medication was found to stopped the growth of tumors in the throat and also increased the effectiveness of chemotherapy, according to lead researcher, Professor Wayne Phillips.

Phillips believed the finding was the biggest breakthrough in the treatment of the cancer in three decades.

"The basic treatment that we use for esophageal cancer hasn't changed much over the last 30-odd years," Phillips told the Australian Broadcasting Corporation (ABC) on Friday.

"This is a completely new approach that we hope will have good efficacy."

The Australian Cancer Council says esophageal cancer, which is often caused by long-term smoking and alcohol use, affects more than 1,000 Australians each year.

Phillips explained the treatment was not a silver bullet for those with esophageal cancer, with chemotherapy still a crucial part of patients entering remission.

"What we've found is that it synergizes with the effects of chemotherapy, so if you add chemotherapy to the tumors, you find a decrease in the tumor growth," Phillips said.

"If you add the drug by itself, you get a decrease, but if you put the two together, we seem to get more than additive effects in blocking the tumor growth."

Clinical trials for further use of the drug could likely begin early next year, with the medication added to the existing treatment process. Endi